Sun Pharma Advanced Research Company
BSE 532872 · ISIN INE232I01014
4 stories, newest first.
- Board meeting on November 2 to approve unaudited results for quarter and half year ended September 30, 2026
- Analyst Kunal expects double-digit constant currency growth in Sun Pharma's specialty business this quarter, with updates awaited on the organon acquisition closing expected in Q1 calendar 2027
- CESTAT upholds order in company's favour, confirms entitlement to refund of CENVAT credit of Rs. 2751 Lakhs
- Sun Pharma signed a global exclusive licensing deal with LIB Therapeutics to commercialize a cholesterol-lowering drug outside the US and China, sparking bullish brokerage views
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.